Literature DB >> 25455877

Assessment of treatment response using PET.

Sandip Basu1, Rakesh Kumar2, Rohit Ranade3.   

Abstract

This article reviews the major treatment response evaluation guidelines in the domain of cancer imaging and how the potential of PET imaging, particularly with fluorodeoxyglucose, is increasingly explored in this important aspect of cancer management. Certain disease-specific response criteria (such as in lymphoma) are also reviewed with emphasis on the changes made over time and the main areas of concern in PET interpretation. The major present clinical applications are illustrated and potential new areas are discussed with regard to clinical applications in the future. Finally, the evolving role of newer and novel PET metrics, which hold promise in treatment response evaluation, is illustrated with examples.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EORTC 1999; Global metabolic burden; Metabolic tumor volume; PERCIST; RECIST1.0; Revised RECIST guideline (version 1.1); WHO criteria; Whole-body metabolic burden

Mesh:

Substances:

Year:  2014        PMID: 25455877     DOI: 10.1016/j.cpet.2014.09.002

Source DB:  PubMed          Journal:  PET Clin        ISSN: 1556-8598


  6 in total

1.  PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.

Authors:  Oke Gerke; Karen Ehlers; Edith Motschall; Poul Flemming Høilund-Carlsen; Werner Vach
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

2.  Head and neck PET/CT therapy response interpretation criteria (Hopkins criteria) - external validation study.

Authors:  Ayse Tuba Kendi; David Brandon; Jeffrey Switchenko; Jeffery Trad Wadsworth; Mark W El-Deiry; Nabil F Saba; David M Schuster; Rathan M Subramaniam
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

3.  Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer.

Authors:  Sarah M Schwarzenböck; Matthias Eiber; Günther Kundt; Margitta Retz; Monique Sakretz; Jens Kurth; Uwe Treiber; Roman Nawroth; Ernst J Rummeny; Jürgen E Gschwend; Markus Schwaiger; Mark Thalgott; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-17       Impact factor: 9.236

4.  PET-CT in the sub-arctic region of Norway 2010-2013. At the edge of what is possible?

Authors:  Jan Norum; Ursula Søndergaard; Erik Traasdahl; Carsten Nieder; Geir Tollåli; Gry Andersen; Rune Sundset
Journal:  BMC Med Imaging       Date:  2015-08-28       Impact factor: 1.930

Review 5.  Imaging Biomarkers in Immunotherapy.

Authors:  Rosalyn A Juergens; Katherine A Zukotynski; Amit Singnurkar; Denis P Snider; John F Valliant; Karen Y Gulenchyn
Journal:  Biomark Cancer       Date:  2016-02-25

6.  [11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy.

Authors:  Sarah M Schwarzenböck; Anna Knieling; Michael Souvatzoglou; Jens Kurth; Katja Steiger; Matthias Eiber; Irene Esposito; Margitta Retz; Hubert Kübler; Jürgen E Gschwend; Markus Schwaiger; Bernd J Krause; Mark Thalgott
Journal:  Oncotarget       Date:  2016-09-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.